Skip to content
Screener

CONMED CNMD Q3 2026 earnings

Reported October 28, 2026 · After market close

Revenue$335.6MMiss by $726.0K
EPS$1.04Beat by $0.04
Revenue estimate$336.3M
EPS estimate$1.00
“Our third quarter organic, constant currency net sales growth was consistent with our expectations and our adjusted diluted EPS exceeded them, reflecting our team's strong execution. Importantly, our net sales growth on an organic, constant currency basis included balanced contributions from both our Orthopedic and General Surgery product lines, which were in turn powered by commercial traction across our key product growth platforms: AirSeal, Buffalo Filter, and BioBrace. Our updated full year guidance reflects this strong performance in the third quarter and our latest outlook as we close out the year.”
Patrick J. Beyer

Next report

Jan 27, 2027 (in 3 months)
Revenue estimate$366.6M
EPS estimate$1.27

Financials

Q3 2026

Income statement

See full
Revenue$335.6M-0.7%
Gross profit$189.1M+13.9%
Operating income$37.1M+213%
Net income$19.8M+592%
EPS (diluted)$0.66+633%

Balance sheet

See full
Cash & equivalents$48.0M+23.2%
Total debt$816.6M-4.6%
Total equity$1.1B+5.1%
Total assets$2.3B-0.8%

Cash flow

See full
Operating cash flow$49.4M-8.0%
CapEx$2.7M-48.3%
Free cash flow$46.7M-3.7%

Valuation & ratios

Valuation

as of 11/02/26
See full
Market cap$1.32B-4.9%
Enterprise value$2.09B-5.3%
P/E18×-3.7×
P/S1×-0.1×

Profitability

See full
Gross margin57.6%+3.4pp
Operating margin9.9%+1.1pp
Net margin5.4%+0.6pp
FCF margin9.7%-1.4pp

Returns & leverage

See full
Return on equity7.1%+0.5pp
Debt / equity0.8×-0.1×
Current ratio1.5×-0.6×

Segments

By geography

See full
Europe, Middle East & Africa$67.6M+15.2%
Asia Pacific$60.4M+12.2%
Americas (excluding the United States)$34.9M+10.9%

By product

See full
General Surgery$186.7M-6.5%
Orthopedic Surgery$148.8M+7.7%

By segment

See full
Single Reportable Segment$335.6M—

FAQ

When did CONMED report Q3 2026 earnings?
CONMED (CNMD) reported Q3 2026 earnings on October 28, 2026 after market close.
What were CONMED's Q3 2026 revenue and EPS?
CONMED reported revenue of $335.6M and eps of $1.04 for Q3 2026.
Did CONMED beat estimates in Q3 2026?
Revenue missed the consensus estimate of $336.3M by $726.0K. EPS beat the consensus estimate of $1.00 by $0.04.
How did CONMED's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.7% from $337.9M a year earlier and eps declined 3.7% from $1.08.
Where can I find CONMED's Q3 2026 SEC filings?
You can read the 8-K earnings release (0000816956-26-000110) and the 10-Q periodic report (0000816956-26-000111) directly on SEC EDGAR. The filing index links above go to sec.gov.